Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUMANTIA-2: NLM-001 + GNab-P + Bot/Bal vs GNab-P in Advanced Pancreatic Cancer
NCT07578337Phase 2Not yet recruiting
- Sponsor
- Nelum
- Start
- Jul 2026
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TAK-441 in pancreatic cancer (PC), sponsored by Nelum. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
TAK-441
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07578337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07578337.